TrimmTrack
Sign in

Eli Lilly (LLY) valuation

Run six valuation models on Eli Lilly with live data: DCF, Reverse DCF, Graham number, Monte Carlo, scenarios and sum-of-the-parts (NAV).

LLY
LLY

Eli Lilly

LLY · Healthcare

Current price

1.215,04 USD

You're trying every model for free, no account needed. Sign up to save your analyses →

Valuation

Market cap
$1.08T
PE (TTM | NTM | +1y)
40.81 | 26.06 | 26.10
Price / Sales
13.60
EV / EBITDA
27.07
Price / Book
34.80

Cash flow

FCF yield(12.41 / 1215.04)
+1.02%
SBC-adjusted FCF yield
—
SBC impact
—

Margins & growth

Profit margin
+33.53%
Operating margin
+54.22%
Quarterly earnings (YoY)
—
Quarterly revenue (YoY)
—

Balance

Cash
$8.95B
Debt
$54.91B
Net position
-$45.96B

Dividend

Dividend yield
+0.57%
Payout ratio
+21.69%
Next payout
9/10/2026

Price (1 year)

+73.27%
$1.22K

Revenue

Q2 23: $8.31BQ2 23Q3 23: $9.5BQ4 23: $9.35BQ4 23Q1 24: $8.77BQ2 24: $11.3BQ2 24Q3 24: $11.44BQ1 25: $12.73BQ1 25Q2 25: $15.56BQ3 25: $17.6BQ3 25Q4 25: $19.29BQ1 26: $19.8BQ1 26$19.8B

EBITDA

Q1 25: $5.77BQ1 25Q2 25: $7.5BQ2 25Q3 25: $7.88BQ3 25Q4 25: $12.14BQ4 25Q1 26: $10.29BQ1 26$12.14B

Net income

Q2 23: $1.76BQ2 23Q3 23: -$57.4MQ4 23: $2.19BQ4 23Q1 24: $2.24BQ2 24: $2.97BQ2 24Q3 24: $970.3MQ1 25: $2.76BQ1 25Q2 25: $5.66BQ3 25: $5.58BQ3 25Q4 25: $6.64BQ1 26: $7.4BQ1 26$7.4B

Free cash flow

Q1 25: -$1.6BQ1 25Q2 25: $1.28BQ2 25Q3 25: $6.03BQ3 25Q4 25: $254.2MQ4 25Q1 26: $2.8BQ1 26$6.03B

EPS

Q2 23: 1.95Q2 23Q3 23: -0.06Q4 23: 2.42Q4 23Q1 24: 2.48Q2 24: 3.28Q2 24Q3 24: 1.07Q1 25: 3.06Q1 25Q2 25: 6.29Q3 25: 6.21Q3 25Q4 25: 7.39Q1 26: 8.26Q1 268.26

Cash & debt

CashDebt
Q2 23 · Cash: $2.69BQ2 23Q3 23 · Cash: $2.38BQ4 23 · Cash: $2.82BQ4 23Q1 24 · Cash: $2.46BQ2 24 · Cash: $3.22BQ2 24Q3 24 · Cash: $3.37BQ1 25 · Cash: $3.09BQ1 25 · Debt: $38.52BQ1 25Q2 25 · Cash: $3.38BQ2 25 · Debt: $39.9BQ3 25 · Cash: $9.79BQ3 25 · Debt: $42.51BQ3 25Q4 25 · Cash: $7.27BQ4 25 · Debt: $42.5BQ1 26 · Cash: $5.28BQ1 26 · Debt: $43.37BQ1 26$43.37B

Return of capital

DividendsBuybacks
Q1 24 · Dividends: $1.17BQ1 24 · Buybacks: $0Q1 24Q1 25 · Dividends: $1.35BQ1 25 · Buybacks: $1.2BQ1 25Q2 25 · Dividends: $1.35BQ2 25 · Buybacks: $692.2MQ2 25Q3 25 · Dividends: $1.35BQ3 25 · Buybacks: $708.1MQ3 25Q4 25 · Dividends: $1.35BQ4 25 · Buybacks: $1.51BQ4 25Q1 26 · Dividends: $1.55BQ1 26 · Buybacks: $2.36BQ1 26$3.9B

Shares outstanding

Q2 23: 949.27MQ2 23Q3 23: 949.3MQ4 23: 949.31MQ2 24: 950.41MQ2 24Q3 24: 950.43MQ4 24: 949.32MQ1 25: 948.17MQ1 25Q1 25: 897.73MQ2 25: 947.74MQ2 25: 896.83MQ2 25Q3 25: 946.46MQ3 25: 895.84MQ4 25: 945.38MQ4 25Q4 25: 894.8MQ1 26: 943.36MQ1 26: 893.5MQ2 26: 941.74MQ2 26950.43M

Stock-based compensation

Q1 24: $159.4MQ1 24Q1 25: $154MQ1 25Q2 25: $184.8MQ2 25Q3 25: $151.1MQ3 25Q4 25: $136.1MQ4 25Q1 26: $161MQ1 26$184.8M

Operating expenses

R&DSG&A
Q2 23 · R&D: $2.36BQ2 23 · SG&A: $1.93BQ2 23Q3 23 · SG&A: $1.8BQ4 23 · SG&A: $1.93BQ4 23Q1 24 · SG&A: $1.95BQ2 24 · SG&A: $2.12BQ2 24Q3 24 · SG&A: $2.1BQ1 25 · R&D: $2.73BQ1 25 · SG&A: $2.47BQ1 25Q2 25 · R&D: $3.34BQ2 25 · SG&A: $2.75BQ3 25 · R&D: $3.47BQ3 25 · SG&A: $2.74BQ3 25Q4 25 · R&D: $3.8BQ4 25 · SG&A: $3.13BQ1 26 · R&D: $3.51BQ1 26 · SG&A: $2.93BQ1 26$6.93B

Source: Yahoo Finance. Quarterly history grows automatically over time as new quarters are published.

Other comparisons

Eli Lilly vs Novo Nordisk

Popular companies

AppleNvidiaTeslaMicrosoftAmazonAlphabet (Google)Meta PlatformsNetflixAMDPalantirBerkshire HathawayJPMorgan ChaseVisaMastercardWalt DisneyCoca-ColaPepsiCoMcDonald'sNikeStarbucksIntelBroadcomQualcommOracleSalesforceAdobePayPalUberAirbnbCoinbase